 Karina Serban
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Emphysema | 11 | 2023 | 280 | 3.930 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 10 | 2022 | 928 | 1.820 |
Why?
| | alpha 1-Antitrypsin | 7 | 2023 | 107 | 1.740 |
Why?
| | alpha 1-Antitrypsin Deficiency | 6 | 2022 | 76 | 1.610 |
Why?
| | Emphysema | 3 | 2021 | 110 | 1.560 |
Why?
| | Smoke | 4 | 2017 | 127 | 1.160 |
Why?
| | Chemokine CX3CL1 | 1 | 2023 | 21 | 0.900 |
Why?
| | Somatomedins | 1 | 2022 | 29 | 0.830 |
Why?
| | Macrophages, Alveolar | 4 | 2021 | 351 | 0.820 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2021 | 7 | 0.790 |
Why?
| | Complement C4 | 1 | 2021 | 26 | 0.780 |
Why?
| | Alveolar Epithelial Cells | 3 | 2019 | 96 | 0.780 |
Why?
| | Complement C1q | 1 | 2021 | 38 | 0.780 |
Why?
| | Prednisolone | 1 | 2021 | 77 | 0.770 |
Why?
| | Arthralgia | 1 | 2021 | 48 | 0.750 |
Why?
| | Exanthema | 1 | 2021 | 76 | 0.740 |
Why?
| | Tobacco Products | 3 | 2016 | 101 | 0.650 |
Why?
| | Blood Proteins | 1 | 2021 | 233 | 0.640 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2019 | 26 | 0.640 |
Why?
| | Metformin | 1 | 2021 | 278 | 0.600 |
Why?
| | Phagocytosis | 2 | 2021 | 352 | 0.540 |
Why?
| | Endocytosis | 2 | 2016 | 151 | 0.520 |
Why?
| | Cell-Derived Microparticles | 1 | 2016 | 58 | 0.510 |
Why?
| | Proteomics | 1 | 2021 | 844 | 0.490 |
Why?
| | Endothelial Cells | 4 | 2023 | 685 | 0.440 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3549 | 0.420 |
Why?
| | Interleukin-6 | 1 | 2016 | 676 | 0.420 |
Why?
| | Apoptosis | 2 | 2016 | 2371 | 0.340 |
Why?
| | Smoking | 4 | 2019 | 1391 | 0.330 |
Why?
| | Cigarette Smoking | 2 | 2022 | 74 | 0.330 |
Why?
| | Lung | 7 | 2023 | 3593 | 0.320 |
Why?
| | Humans | 25 | 2023 | 114937 | 0.270 |
Why?
| | Lipopolysaccharides | 4 | 2023 | 817 | 0.270 |
Why?
| | Mice | 10 | 2023 | 14936 | 0.250 |
Why?
| | Animals | 14 | 2023 | 31839 | 0.230 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2023 | 18 | 0.230 |
Why?
| | Caspase 3 | 2 | 2016 | 238 | 0.220 |
Why?
| | Endothelium | 1 | 2023 | 112 | 0.210 |
Why?
| | Vascular System Injuries | 1 | 2023 | 64 | 0.200 |
Why?
| | Myosins | 1 | 2022 | 128 | 0.200 |
Why?
| | Pancreatic Elastase | 2 | 2022 | 67 | 0.200 |
Why?
| | Mice, Inbred C57BL | 5 | 2022 | 4719 | 0.200 |
Why?
| | Endopeptidases | 1 | 2022 | 72 | 0.200 |
Why?
| | Cell Communication | 1 | 2023 | 280 | 0.200 |
Why?
| | Cell Death | 3 | 2019 | 325 | 0.200 |
Why?
| | Molecular Docking Simulation | 1 | 2022 | 102 | 0.200 |
Why?
| | Ligands | 1 | 2023 | 565 | 0.190 |
Why?
| | Niemann-Pick Disease, Type A | 1 | 2021 | 5 | 0.190 |
Why?
| | Niemann-Pick Disease, Type B | 1 | 2021 | 5 | 0.190 |
Why?
| | Lysophospholipase | 1 | 2021 | 11 | 0.190 |
Why?
| | Protease Inhibitors | 1 | 2022 | 99 | 0.190 |
Why?
| | Patient Care Management | 1 | 2021 | 54 | 0.190 |
Why?
| | Peptide Hydrolases | 1 | 2022 | 106 | 0.190 |
Why?
| | Receptors, Glucocorticoid | 1 | 2022 | 131 | 0.190 |
Why?
| | Sphingomyelin Phosphodiesterase | 1 | 2021 | 22 | 0.190 |
Why?
| | PPAR gamma | 1 | 2022 | 183 | 0.180 |
Why?
| | Rituximab | 1 | 2021 | 151 | 0.180 |
Why?
| | Monocytes | 1 | 2023 | 504 | 0.180 |
Why?
| | Macrophages | 3 | 2022 | 1266 | 0.180 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 169 | 0.180 |
Why?
| | Biomarkers | 2 | 2022 | 3418 | 0.180 |
Why?
| | Glucosylceramides | 1 | 2019 | 7 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 243 | 0.170 |
Why?
| | Case-Control Studies | 2 | 2017 | 3008 | 0.170 |
Why?
| | Immunologic Factors | 1 | 2021 | 221 | 0.170 |
Why?
| | Cells, Cultured | 5 | 2019 | 3897 | 0.170 |
Why?
| | Glycoproteins | 1 | 2021 | 305 | 0.160 |
Why?
| | Caspase 6 | 2 | 2016 | 5 | 0.160 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2019 | 22 | 0.160 |
Why?
| | Caspase 7 | 2 | 2016 | 22 | 0.160 |
Why?
| | Inflammation | 3 | 2023 | 2485 | 0.160 |
Why?
| | Alpha-Globulins | 1 | 2018 | 20 | 0.150 |
Why?
| | Sphingolipids | 1 | 2018 | 58 | 0.150 |
Why?
| | X-Ray Microtomography | 1 | 2018 | 74 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2018 | 65 | 0.150 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1355 | 0.140 |
Why?
| | ADAM17 Protein | 1 | 2017 | 31 | 0.140 |
Why?
| | Collagen | 1 | 2019 | 416 | 0.140 |
Why?
| | THP-1 Cells | 1 | 2016 | 20 | 0.140 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2018 | 72 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2022 | 647 | 0.140 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 189 | 0.130 |
Why?
| | Middle Aged | 4 | 2021 | 26806 | 0.130 |
Why?
| | Pneumonia | 1 | 2021 | 568 | 0.130 |
Why?
| | Extracellular Matrix | 1 | 2019 | 436 | 0.130 |
Why?
| | Influenza, Human | 1 | 2021 | 546 | 0.130 |
Why?
| | Scavenger Receptors, Class B | 1 | 2015 | 9 | 0.130 |
Why?
| | Acute Lung Injury | 1 | 2018 | 300 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 590 | 0.120 |
Why?
| | Fibroblasts | 1 | 2019 | 839 | 0.120 |
Why?
| | Transcytosis | 1 | 2014 | 9 | 0.120 |
Why?
| | Alginates | 1 | 2014 | 44 | 0.120 |
Why?
| | Autoantibodies | 1 | 2021 | 1354 | 0.110 |
Why?
| | Pulmonary Alveoli | 1 | 2016 | 374 | 0.110 |
Why?
| | Rats | 3 | 2017 | 4963 | 0.110 |
Why?
| | Endothelium, Vascular | 2 | 2016 | 848 | 0.110 |
Why?
| | Prognosis | 1 | 2021 | 3344 | 0.110 |
Why?
| | Male | 7 | 2021 | 55663 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 185 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2211 | 0.100 |
Why?
| | Pseudomonas aeruginosa | 1 | 2014 | 299 | 0.100 |
Why?
| | Aging | 1 | 2021 | 1621 | 0.100 |
Why?
| | Acrospiroma | 1 | 2010 | 1 | 0.090 |
Why?
| | Sweat Gland Neoplasms | 1 | 2010 | 6 | 0.090 |
Why?
| | Genital Neoplasms, Male | 1 | 2010 | 6 | 0.090 |
Why?
| | Scrotum | 1 | 2010 | 24 | 0.090 |
Why?
| | Ceramides | 2 | 2023 | 94 | 0.090 |
Why?
| | Female | 6 | 2021 | 59581 | 0.090 |
Why?
| | Muscle, Smooth | 1 | 2011 | 147 | 0.090 |
Why?
| | Histoplasmosis | 1 | 2009 | 16 | 0.090 |
Why?
| | Trachea | 1 | 2011 | 235 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 400 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2009 | 117 | 0.080 |
Why?
| | Epithelial Cells | 3 | 2021 | 958 | 0.080 |
Why?
| | Bone Marrow | 1 | 2009 | 245 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2021 | 2587 | 0.080 |
Why?
| | Cystic Fibrosis | 1 | 2014 | 956 | 0.060 |
Why?
| | Angiopoietins | 1 | 2022 | 13 | 0.050 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2022 | 35 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2018 | 1953 | 0.050 |
Why?
| | Fingolimod Hydrochloride | 1 | 2022 | 30 | 0.050 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2022 | 61 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 238 | 0.050 |
Why?
| | Adult | 4 | 2017 | 30608 | 0.050 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2021 | 10 | 0.050 |
Why?
| | Th1-Th2 Balance | 1 | 2021 | 10 | 0.050 |
Why?
| | Chitinases | 1 | 2021 | 9 | 0.050 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2021 | 53 | 0.050 |
Why?
| | CD11 Antigens | 1 | 2021 | 31 | 0.050 |
Why?
| | Cell Size | 1 | 2021 | 81 | 0.050 |
Why?
| | Lectins | 1 | 2021 | 44 | 0.050 |
Why?
| | CD11b Antigen | 1 | 2021 | 58 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 496 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 1 | 2019 | 33 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2022 | 451 | 0.040 |
Why?
| | Eosinophils | 1 | 2021 | 280 | 0.040 |
Why?
| | NF-kappa B | 1 | 2022 | 637 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2019 | 101 | 0.040 |
Why?
| | Mucociliary Clearance | 1 | 2018 | 42 | 0.040 |
Why?
| | Autophagy | 1 | 2019 | 234 | 0.040 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 344 | 0.040 |
Why?
| | Gene Expression | 1 | 2021 | 1422 | 0.030 |
Why?
| | Neutrophils | 1 | 2021 | 1164 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 1022 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1153 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2015 | 194 | 0.030 |
Why?
| | Homeostasis | 1 | 2018 | 576 | 0.030 |
Why?
| | Hexuronic Acids | 1 | 2014 | 24 | 0.030 |
Why?
| | Glucuronic Acid | 1 | 2014 | 27 | 0.030 |
Why?
| | Polysaccharide-Lyases | 1 | 2014 | 12 | 0.030 |
Why?
| | Virulence | 1 | 2014 | 228 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1325 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2324 | 0.030 |
Why?
| | Protein Binding | 1 | 2018 | 1897 | 0.030 |
Why?
| | Signal Transduction | 2 | 2018 | 4525 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2014 | 1227 | 0.020 |
Why?
| | Contractile Proteins | 1 | 2011 | 16 | 0.020 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2011 | 37 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2011 | 61 | 0.020 |
Why?
| | Hypertrophy | 1 | 2011 | 111 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2011 | 78 | 0.020 |
Why?
| | Bone Marrow Examination | 1 | 2009 | 7 | 0.020 |
Why?
| | Dogs | 1 | 2011 | 337 | 0.020 |
Why?
| | Histoplasma | 1 | 2009 | 14 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 281 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2010 | 142 | 0.020 |
Why?
| | Amphotericin B | 1 | 2009 | 30 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 236 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 790 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2009 | 129 | 0.020 |
Why?
| | Actins | 1 | 2011 | 382 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2014 | 725 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2010 | 425 | 0.020 |
Why?
| | Muscle Contraction | 1 | 2011 | 399 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6125 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2010 | 1180 | 0.020 |
Why?
| | Phosphorylation | 1 | 2011 | 1572 | 0.020 |
Why?
| | Biopsy | 1 | 2009 | 1045 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2011 | 2199 | 0.010 |
Why?
| | Disease Progression | 1 | 2009 | 2392 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2010 | 4427 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 2042 | 0.010 |
Why?
| | Aged | 1 | 2012 | 19122 | 0.010 |
Why?
|
|
Serban's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|